Goldman has a new favorite biotech because of potential Alzheimer's 'blockbuster'

Research analyst Terence Flynn added Biogen to Goldman Sachs' Americas Conviction List on optimism its Alzheimer's drug may be the first to successfully slow the progression of the disease.
00:45
Wed, Aug 16 201710:46 AM EST